Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.
Red Cross Oral Pain Relief benzocaine 200 mg/mL Liquid, 1 bottle — NDC 10742-8902-1 (Billing 10742-8902-01)
by The Mentholatum Company · 1 BOTTLE in 1 BLISTER PACK / 3.7 mL in 1 BOTTLE
This is a package of 1 bottle of Red Cross Oral Pain Relief benzocaine 200 mg/mL Liquid from The Mentholatum Company, marketed since Jun 2013 and currently FDA-listed. It is this product's only package size.
NDC 10742-8902-01
🏷️ FDA NDC (as labeled)
10742-8902-1
billing pads the package segment with a zero
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
NDC database record
One package, one record: these facts belong to NDC 10742-8902-1 alone.
- Record
- FDA NDC Directory package listing · Human OTC drug
- Code segments
- 10742 labeler · 8902 product · 1 package
- Package marketed since
- Jun 1, 2013
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 1074289021 1
- FDA record last changed
- Jul 24, 2026
⚠️
Other active recalls for Benzocaine (different manufacturers) — 6 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · May 21, 2026 — Defective container:may contain bottles with incomplete seals (Keystone Industries) · FDA recall D-0602-2026
Class II · May 21, 2026 — Defective container:may contain bottles with incomplete seals (Keystone Industries) · FDA recall D-0605-2026
Class II · May 21, 2026 — Defective container:may contain bottles with incomplete seals (Keystone Industries) · FDA recall D-0601-2026
Class II · May 21, 2026 — Defective container:may contain bottles with incomplete seals (Keystone Industries) · FDA recall D-0603-2026
Class II · May 21, 2026 — Defective container:may contain bottles with incomplete seals (Keystone Industries) · FDA recall D-0604-2026
Class II · May 21, 2026 — Defective container:may contain bottles with incomplete seals (Keystone Industries) · FDA recall D-0606-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
FDA NDC (as labeled)
10742-8902-1
Product NDC
10742-8902
11-digit billing NDC
10742890201
RxCUI
308657
UNII
U3RSY48JW5
Application #
M022
SPL Set ID
cbd41429-f730-4577-9f06-ef1831cf62e1
Established class (EPC)
Standardized Chemical Allergen
Physiologic effect
Increased Histamine Release; Cell-mediated Immunity
Chemical class
Allergens
DEA schedule
Non-controlled
Marketing category
OTC MONOGRAPH DRUG
Marketing status
On market
FDA listing status
Listed (active directory)
Marketing start
2013-06-01
Route
TOPICAL
Dosage form
LIQUID
Substance
BENZOCAINE
Quick answers
- RxCUI (RxNorm): 308657
Why two NDCs?
The FDA registers this code as 10742-8902-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 10742-8902-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Standardized Chemical Allergen class.
Pharmacologic class
Standardized Chemical Allergen
Drug family (ATC)
Local anesthetics, Anesthetics for topical use, Esters of aminobenzoic acid
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
🧪 What is this product?
Red Cross Oral Pain Relief is a topical liquid containing benzocaine, a local anesthetic. It is typically applied directly to the mouth and gums to numb or reduce pain from minor dental discomfort, canker sores, or similar oral irritation. This is an over-the-counter monograph product, meaning it is marketed under FDA rules for its category rather than as an individually approved application.
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Benzocaine — tap one for details:
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
💬 Questions about benzocaine?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 4, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 10742-8902-01 You're viewing this Main listing | 1 BOTTLE in 1 BLISTER PACK / 3.7 mL in 1 BOTTLE | 2013-06-01 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Benzocaine 20% 200 mg/mL 00121-1077-25 | PAI | 25 pouches | — | — | FDA listed | — |
| HurriCaine Topical Anesthetic Liquid 200 mg/g 00283-0569-02 | Beutlich | 2 g | — | — | Discontinued | — |
| HurriCaine Topical Anesthetic Liquid 200 mg/g 00283-1886-17 | Beutlich | 1 g | — | — | FDA listed | — |
| Walgreens Mouth Sore Relief 200 mg/mL 00363-5334-00 | Walgreens | 1 bottle | — | — | FDA listed | — |
| Walgreens Maximum Strength 20 g/100g 00363-5820-58 | Walgreens | 1 bottle | — | — | FDA listed | — |
| Kank-A Mouth Pain 200 mg/mL 10157-9477-01 | Blistex | 9.75 ml | — | — | FDA listed | — |
| Red Cross Oral Pain Relief 200 mg/mLthis 10742-8902-01 | The | 1 bottle | — | — | FDA listed | — |
| Rite Aid Maximum Strength 20 g/100g 11822-0345-09 | Rite | 1 bottle | — | — | FDA listed | — |
| Rite Aid Professional Strength 20 g/100g 11822-5340-08 | Rite | 1 bottle | — | — | FDA listed | — |
| Topcare Maximum Strength 20 g/100g 36800-0443-48 | Topco | 1 bottle | — | — | FDA listed | — |
| Dental Relief 200 mg/g 42961-0810-03 | Cintas | 10 packets | — | — | FDA listed | — |
| Rexall Maximum Strength 20 g/100mL 55910-0346-79 | Rexall | 1 bottle | — | — | FDA listed | — |
| CVS Pharmacy Maximum Strength 20 g/100g 59779-0743-89 | CVS | 1 bottle | — | — | FDA listed | — |
| Mouth Sore Relief Professional Strength 200 mg/g 59779-0830-38 | CVS | 1 bottle | — | — | FDA listed | — |
| DenTek Instant Pain Relief Maximum Strength 200 mg/mL 60630-0078-01 | DenTek | 1 vial | — | — | FDA listed | — |
| Dental Relief 200 mg/g 68421-8100-03 | Cintas | 10 packets | — | — | FDA listed | — |
| Anesgerm LA MUELA Fast Pain Relief 200 mg/mL 73635-7101-05 | Germa | 1 bottle | — | — | Discontinued | — |
| Oral Anesthetic Liquid 20 g/100g 79481-0118-09 | Meijer, | 1 bottle | — | — | FDA listed | — |
| Anbesol Maximum Strength 200 mg/mL 80070-0230-41 | Foundation | 1 bottle | — | — | FDA listed | — |
| Dolodent Maximum Strength 200 mg/mL 55758-0505-01 | Pharmadel | 1 bottle | — | — | FDA listed | — |
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
🏛️
2013
On the market since
Jun 2013
📍
2026
Currently FDA-listed
13 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 3VRD35U26C
A natural extract from licorice root, ammonium glycyrrhizate is used as a flavoring agent and sweetener in medicines. It may also help soothe irritated tissues in the mouth or throat.
-
UNII B697894SGQ
Polyethylene glycol 400 is a clear, thick liquid made from petroleum-derived polymers. It acts as a solvent and humectant in medicines, helping dissolve active ingredients and retain moisture in the formulation.
-
UNII 6DC9Q167V3
Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
-
UNII 5101OP7P2I
Saccharin calcium is an artificial sweetener made from saccharin combined with calcium. It's used in medicines to make tablets or liquids taste better so they're easier to take.
4 inactive ingredients listed in the exact product block matched to this NDC.
The official label also statesammonium glycyrrhizate, flavor, polyethylene glycol, propylene glycol, saccharin calcium
Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.
Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed —
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 3, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
Manufacturer & labeler
LabelerThe Mentholatum Company
FDA applicationM022 (OTC MONOGRAPH DRUG)
Labeler code10742
First marketedJun 2013
Product typeHuman Otc Drug
Portfolio108 products on file
More NDCs from The Mentholatum Company labeler code 10742
- Mentholatum Cherry Vaporizing Rub camphor, eucalyptus oil, menthol 47 mg/g; 12 mg/g; 26 mg/g Ointment NDC 10742-8731-1
- Softlips Oasis Pineapple Coconut, Peach Mango, Strawberry Kiwi dimethicone, oxybenzone, octinoxate 20 mg/g; 75 mg/g; 40 mg/g Stick NDC 10742-8744-1
- Softlips Oasis Pineapple Coconut dimethicone, oxybenzone, octinoxate 20 mg/g; 75 mg/g; 40 mg/g Stick NDC 10742-8745-1
- Softlips Oasis Watermelon Blackberry dimethicone, oxybenzone, octinoxate 20 mg/g; 75 mg/g; 40 mg/g Stick NDC 10742-8747-1
- Mentholatum Medicated Lip Balm Original dimethicone, octinoxate, octisalate 10 mg/g; 75 mg/g; 50 mg/g Ointment NDC 10742-8865-1
- Mentholatum Medicated Lip Balm Cherry dimethicone, octinoxate, octisalate 10 mg/g; 75 mg/g; 50 mg/g Ointment NDC 10742-8893-1
- Red Cross Canker Sore benzocaine 200 mg/g Ointment NDC 10742-8915-1
- Mentholatum Natural Ice Sport SPF 30 avobenzone, dimethicone, octinoxate, octisalate 30 mg/g; 10 mg/g; 75 mg/g; 50 mg/g Ointment NDC 10742-8980-3
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
FDA label — Drug Facts FDA SPL
The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage
⏱️ Dosage and Administration
⚠️ Warnings
🧪 Active Ingredient
🧪 Inactive Ingredients
🎯 Purpose
📄 Do Not Use
📄 When Using This Product
📄 Stop Use and Ask a Doctor If
📄 Keep Out of Reach of Children
📄 Package Label / Principal Display Panel
🎯 Indications and Usage ▾
Uses temporarily relieves pain associated with ▪ toothache ▪ canker sores ▪ minor mouth irritation or injury of the mouth and gums caused by dentures or braces
⏱️ Dosage and Administration ▾
Directions using tweezers, immerse cotton pellet in medication apply pellet to affected area, then remove adults and children 2 years and over: use up to 4 times daily or as directed by a dentist or doctor children under 12 years: supervise while using this product children under 2 years: do not use
⚠️ Warnings ▾
Warnings Methemoglobinemia warning: Use of this product may cause methemoglobinemia, a serious condition that must be treated promptly because it reduces the amount of oxygen carried in blood. This can occur even if you have used this product before. Stop use and seek immediate medical attention if you or a child in your care develops: ▪ pale, gray, or blue colored skin (cyanosis) ▪ headache ▪ rapid heart rate ▪ shortness of breath ▪ dizziness or lightheadedness ▪ fatigue or lack of energy Allergy alert: do not use this product if you have a history of allergy to local anesthetics such as procaine, butacaine, benzocaine or other “caine” anesthetics Do Not Use for teething in children under 2 years of age When using this product do not use for more than 7 days unless directed by a dentist or doctor do not exceed recommended dosage Stop use and ask a doctor if sore mouth symptoms do not improve in 7 days swelling, rash, or fever develops irritation, pain, or redness persists or worsens
🧪 Active Ingredient ▾
Active ingredient Benzocaine 20%
🧪 Inactive Ingredients ▾
Inactive Ingredients ammonium glycyrrhizate, flavor, polyethylene glycol, propylene glycol, saccharin calcium
🎯 Purpose ▾
Purpose Oral pain reliever
📄 Do Not Use ▾
Do Not Use for teething in children under 2 years of age
📄 When Using This Product ▾
When using this product do not use for more than 7 days unless directed by a dentist or doctor do not exceed recommended dosage
📄 Stop Use and Ask a Doctor If ▾
Stop use and ask a doctor if sore mouth symptoms do not improve in 7 days swelling, rash, or fever develops irritation, pain, or redness persists or worsens
📄 Keep Out of Reach of Children ▾
Keep Out of Reach of Children If more than used for pain is accidentally swallowed, get medical help or contact a Poison Control Center right away.
📄 Package Label / Principal Display Panel ▾
Package/Label Principal Display Panel Red Cross Oral Pail Oral Anesthetic
Principal Display Panel Drug Facts
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Red Cross Oral Pain Relief (this brand).
Top reported reactions
Age at onset
Reporter sex
Male · 35%
Female · 65%
Unknown · 1%
Serious outcomes
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
About this NDC listing & data coverage
Over-the-counter (OTC) product
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Otc Monograph Drug". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by The Mentholatum Company. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
The Mentholatum Company is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as an over-the-counter product, so it does not require a prescription. Follow the package directions, and ask your pharmacist if you are unsure whether it is right for you.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.